Journal
JOURNAL OF BLOOD MEDICINE
Volume 12, Issue -, Pages 795-807Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/JBM.S267938
Keywords
Waldenstrom's macroglobulinemia; IgM-MGUS; pathology; biology; diagnosis; prognosis
Categories
Funding
- Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness [PI18/01866, CIBERONC-CB16/12/00233]
- Cancer Research UK [C355/A26819]
- FC AECC
- AIRC [CEI-2010-1-0010]
Ask authors/readers for more resources
Waldenstrom macroglobulinemia (WM) is a bone marrow neoplastic disorder with lymphoplasmacytic differentiation. The diagnosis has been simplified with the identification of somatic mutations, such as the L265P mutation in the MYD88 gene. Genetic evaluation of patients can help predict the risk of disease transformation.
After 77 years since the initial description, Waldenstrom macroglobulinemia (WM) remains as a bone marrow neoplastic disorder with lymphoplasmacytic differentiation oversecreting a monoclonal immunoglobulin M (IgM). However, many biological and genetic aspects of this entity have been unraveled and it is now easy to correctly diagnose patients with this illness. The diagnosis requires the presence of a monoclonal IgM component and bone marrow lymphoid infiltration must be demonstrated. In addition, other small B-cell lymphoid neoplasms with plasma cell differentiation must be discarded. Although the clinical picture is highly heterogeneous, the diagnosis is much easier today compared to the past, since now we can demonstrate the presence of somatic mutations, especially the L265P mutation in the MYD88 gene, highly characteristic of WM (>90% of the patients), followed by the WHIM-like mutations in the CXCR4 gene (similar to 35%). The identification of these mutations is very important, because they can modulate the response to new treatments with Bruton's tyrosine kinase (BTK) inhibitors. Thus, the conventional prognostic factors that predict the outcome of these patients (anemia, thrombopenia, high M component, high B2M, and advanced age), must be complemented with the genetic evaluation of the patient, that can help us in the prediction of the risk of transformation from asymptomatic to symptomatic forms (Del6q) and/or from indolent forms of the disease to aggressive lymphomas (CD79b mutations).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available